These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 3234317

  • 1. Human acid beta-glucosidase: inhibition studies using glucose analogues and pH variation to characterize the normal and Gaucher disease glycon binding sites.
    Osiecki-Newman K, Legler G, Grace M, Dinur T, Gatt S, Desnick RJ, Grabowski GA.
    Enzyme; 1988; 40(4):173-88. PubMed ID: 3234317
    [Abstract] [Full Text] [Related]

  • 2. Human acid beta-glucosidase: use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites.
    Osiecki-Newman K, Fabbro D, Legler G, Desnick RJ, Grabowski GA.
    Biochim Biophys Acta; 1987 Sep 02; 915(1):87-100. PubMed ID: 2956992
    [Abstract] [Full Text] [Related]

  • 3. Human acid beta-glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes.
    Grabowski GA, Osiecki-Newman K, Dinur T, Fabbro D, Legler G, Gatt S, Desnick RJ.
    J Biol Chem; 1986 Jun 25; 261(18):8263-9. PubMed ID: 3087971
    [Abstract] [Full Text] [Related]

  • 4. Use of activators and inhibitors to define the properties of the active site of normal and Gaucher disease lysosomal beta-glucosidase.
    Gatt S, Dinur T, Osiecki K, Desnick RJ, Grabowski GA.
    Enzyme; 1985 Jun 25; 33(2):109-19. PubMed ID: 3924590
    [Abstract] [Full Text] [Related]

  • 5. Analyses of catalytic activity and inhibitor binding of human acid beta-glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations.
    Grace ME, Graves PN, Smith FI, Grabowski GA.
    J Biol Chem; 1990 Apr 25; 265(12):6827-35. PubMed ID: 2324100
    [Abstract] [Full Text] [Related]

  • 6. Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.
    Grabowski GA, Dinur T, Osiecki KM, Kruse JR, Legler G, Gatt S.
    Am J Hum Genet; 1985 May 25; 37(3):499-510. PubMed ID: 4003396
    [Abstract] [Full Text] [Related]

  • 7. Human acid beta-glucosidase: affinity purification of the normal placental and Gaucher disease splenic enzymes on N-alkyl-deoxynojirimycin-sepharose.
    Osiecki-Newman KM, Fabbro D, Dinur T, Boas S, Gatt S, Legler G, Desnick RJ, Grabowski GA.
    Enzyme; 1986 May 25; 35(3):147-53. PubMed ID: 2944742
    [Abstract] [Full Text] [Related]

  • 8. Human lysosomal beta-glucosidase: kinetic characterization of the catalytic, aglycon, and hydrophobic binding sites.
    Grabowski GA, Gatt S, Kruse J, Desnick RJ.
    Arch Biochem Biophys; 1984 May 15; 231(1):144-57. PubMed ID: 6426391
    [Abstract] [Full Text] [Related]

  • 9. Glucosylceramidase from calf spleen. Characterization of its active site with 4-n-alkylumbelliferyl beta-glucosides and N-alkyl derivatives of 1-deoxynojirimycin.
    Legler G, Liedtke H.
    Biol Chem Hoppe Seyler; 1985 Dec 15; 366(12):1113-22. PubMed ID: 2936366
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of a heat-stable factor in human placenta on glucosylceramidase, glucosylsphingosine glucosyl hydrolase, and acid beta-glucosidase activities.
    Vaccaro AM, Muscillo M, Tatti M, Salvioli R, Gallozzi E, Suzuki K.
    Clin Biochem; 1987 Dec 15; 20(6):429-33. PubMed ID: 3124976
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 2,3-di-O-tetradecyl-1-O-(beta-D-glucopyranosyl)-sn-glycerol is a substrate for human glucocerebrosidase.
    Glew RH, Gopalan V, Hubbell CA, Devraj RV, Lawson RA, Diven WF, Mannock DA.
    Biochem J; 1991 Mar 01; 274 ( Pt 2)(Pt 2):557-63. PubMed ID: 1900989
    [Abstract] [Full Text] [Related]

  • 14. Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.
    Grabowski GA, Goldblatt J, Dinur T, Kruse J, Svennerholm L, Gatt S, Desnick RJ.
    Am J Med Genet; 1985 Jul 01; 21(3):529-49. PubMed ID: 3927728
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen.
    Aerts JM, Donker-Koopman WE, van der Vliet MK, Jonsson LM, Ginns EI, Murray GJ, Barranger JA, Tager JM, Schram AW.
    Eur J Biochem; 1985 Aug 01; 150(3):565-74. PubMed ID: 4018098
    [Abstract] [Full Text] [Related]

  • 17. Gaucher's disease II. Studies on the kinetics of beta-glucosidase and the effects of sodium taurocholate in normal and Gaucher tissues.
    Choy FY, Davidson RG.
    Pediatr Res; 1980 Jan 01; 14(1):54-9. PubMed ID: 6767218
    [Abstract] [Full Text] [Related]

  • 18. Specfic irreversible inhibition of sweet-almond beta-glucosidase by some beta-glycopyranosylepoxyalkanes and beta-d-glucopyranosyl isothiocyanate.
    Shulman ML, Shiyan SD, Khorlin AY.
    Biochim Biophys Acta; 1976 Aug 12; 445(1):169-81. PubMed ID: 8136
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The enzymatic hydrolysis of 6-acylamino-4-methylumbelliferyl-beta-D-glucosides: identification of a novel human acid beta-glucosidase.
    Mikhaylova M, Wiederschain G, Mikhaylov V, Aerts JM.
    Biochim Biophys Acta; 1996 Oct 07; 1317(1):71-9. PubMed ID: 8876629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.